Kiniksa Pharmaceuticals International Plc (KNSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 243,600 | 214,266 | 202,127 | 180,855 | 156,797 |
| Cost of Goods | 23,572 | 20,796 | 20,945 | 20,257 | 18,603 |
| Gross Profit | 220,028 | 193,470 | 181,182 | 160,598 | 138,194 |
| Operating Expenses | 193,406 | 164,999 | 162,359 | 136,834 | 118,637 |
| Operating Income | 27,194 | 29,267 | 19,768 | 24,021 | 20,160 |
| Other Income | 3,951 | 3,414 | 3,501 | 3,136 | 2,717 |
| Pre-tax Income | 31,145 | 32,681 | 23,269 | 27,157 | 22,877 |
| Income Tax | 5,713 | 10,089 | 9,070 | 8,722 | 5,045 |
| Net Income Continuous | 25,432 | 22,592 | 14,199 | 18,435 | 17,832 |
| Net Income | $25,432 | $22,592 | $14,199 | $18,435 | $17,832 |
| EPS Basic Total Ops | 0.33 | 0.30 | 0.19 | 0.25 | 0.24 |
| EPS Basic Continuous Ops | 0.33 | 0.30 | 0.19 | 0.25 | 0.24 |
| EPS Diluted Total Ops | 0.30 | 0.27 | 0.18 | 0.23 | 0.23 |
| EPS Diluted Continuous Ops | 0.30 | 0.27 | 0.18 | 0.23 | 0.23 |
| EPS Diluted Before Non-Recurring Items | N/A | 0.27 | 0.17 | 0.23 | 0.23 |
| EBITDA(a) | $27,666 | $29,735 | $20,235 | $24,405 | $20,518 |